Diseases /
Non-Squamous Non-Small Cell Lung Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A non-small cell lung carcinoma without evidence of squamous differentiation. [1]
Biomarker-Directed Therapies
Of the biomarker-directed therapies for non-squamous non-small cell lung carcinoma, 8 are FDA-approved in at least one setting and 3 have NCCN guidelines in at least one setting [3].
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must not match any of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Atezolizumab (TECENTRIQ®, Genentech, Inc.), is approved in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. |
Atezolizumab + Carboplatin + Nab-Paclitaxel +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must not match any of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: FDA approved approved atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. |
Pembrolizumab + Pemetrexed + Platinum Chemotherapy +
Disease is predicted to be sensitive: -
There are 75 clinical trials for non-squamous non-small cell lung carcinoma, of which 75 are open and 0 are completed or closed. Of the trials that contain non-squamous non-small cell lung carcinoma as an inclusion criterion, 10 are phase 1 (10 open), 5 are phase 1/phase 2 (5 open), 35 are phase 2 (35 open), 24 are phase 3 (24 open), and 1 is phase 4 (1 open).
EGFR, PD-L1, and KRAS are the most frequent gene inclusion criteria for non-squamous non-small cell lung carcinoma clinical trials [3].
Pemetrexed, carboplatin, and pembrolizumab are the most common interventions in non-squamous non-small cell lung carcinoma clinical trials.
Significant Genes in Non-Squamous Non-Small Cell Lung Carcinoma
ALK +
ALK is an inclusion eligibility criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ALK status and non-squamous non-small cell lung carcinoma as inclusion criteria, 3 are phase 2 (3 open) [3].
BRAF +
BRAF is an inclusion eligibility criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].
EGFR +
EGFR is an inclusion eligibility criterion in 15 clinical trials for non-squamous non-small cell lung carcinoma, of which 15 are open and 0 are closed. Of the trials that contain EGFR status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), 7 are phase 3 (7 open), and 1 is phase 4 (1 open) [3].
ERBB2 +
ERBB2 is an inclusion eligibility criterion in 5 clinical trials for non-squamous non-small cell lung carcinoma, of which 5 are open and 0 are closed. Of the trials that contain ERBB2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [3].
KEAP1 +
KEAP1 is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KEAP1 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
KRAS +
KRAS is an inclusion eligibility criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [3].
MET +
MET is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
NFE2L2 +
NFE2L2 is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFE2L2 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
RET +
RET is an inclusion eligibility criterion in 3 clinical trials for non-squamous non-small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RET status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 2 are phase 3 (2 open) [3].
ROS1 +
ROS1 is an inclusion eligibility criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
